Lagevrio Reduces Severe COVID-19 Risk

The BMJ today published a study based on U.S. VA data that concluded among people at high risk of progression to severe COVID-19-19, molnupiravir (Lagevrio™) use within five days of SARS-CoV-2 virus infection may be a viable approach to reduce the risk of post-acute sequelae of SARS-CoV-2 (PASC).

Led by VA Saint Louis Health Care System researchers, this study found molnupiravir was also associated with reduced risk of PASC in people who had not received a covid-19 vaccine, had received one or two vaccine doses, and had received a booster dose, and in people with primary SARS-CoV-2 infection and reinfection.

The researchers wrote they don't know whether this study's findings would apply to people without risk factors for severe COVID-19.

As of April 25, 2023, Lagevrio is approved or authorized for use in more than 25 countries, including the United States.